Delivery Order SPE2DB24D1205-SPE2DB25FCYJD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) with a contract ceiling value of $4,027.70. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by September 30, 2025, with fulfillment occurring at the vendor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed-price contract with a ceiling value of $4,027.70. This non-set-aside delivery order is scheduled for completion by August 18, 2025, with performance conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued against the vendor's larger...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (quantity: 30 units) with a ceiling value of $14,704.48. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) with a ceiling value of $4,027.70. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement valued through December 2026. The award carries no set-aside designation, indicating it was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed price contract valued at $4,027.70, with an ultimate completion date of August 15, 2025. This non-competitive delivery order was issued on July 25, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award represents a child order under the company's larger...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for $8,055.40 on August 21, 2025, for the supply of Ingrezza 80 mg capsules (30-count units). The contract represents a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units) under a firm fixed-price contract with a ceiling value of $3,676.12. The delivery order, issued on July 18, 2025, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $3,676.12 to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (30-unit quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 12, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ingrezza 40 mg capsules (30-count) with a ceiling value of $3,676.12. This is a firm fixed price delivery order with an ultimate completion date of September 24, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is...
- The Defense Logistics Agency awarded a $3,676.12 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ingrezza 40 mg capsules (30-count units). The contract, which is not set-aside, carries a firm fixed price structure with an ultimate completion date of August 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This award represents a child contract under...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCYJDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 9, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) with a ceiling value of $4,027.70 and a firm fixed price structure. This order is set to be completed by July 30, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location, leveraging its established position as a major pharmaceutical distributor and critical vendor for federal medical procurement. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs. Ingrezza, an antipsychotic medication used for involuntary movement disorders, exemplifies the specialized pharmaceutical commodities the company delivers under this vehicle to support Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 7/9/25 |